Oscar Health downgraded to Underperform at BofA after Trump win

As previously reported, BofA downgraded Oscar Health (OSCR) to Underperform from Neutral with a price target of $13.50, down from $21, as the firm argues that a change in administration “dramatically increases” the odds of that the enhanced exchange subsidies expire and that the regulatory environment tightens. The firm is lowering its EPS estimates in 2027 to 85c, which is now 60% below consensus, the analyst tells investors.